---
layout: theophylline_style
title: IL2-CD25 aptermer
date: 2024-05-15 00:00:00
author: Baowei Huang, Yuxuan Sun
categories: Aptamer
tags:
- Category:Cell
- GC:66.67
- GC:70.59
- Length:51
- Named:IL2–CD25 complexes_Tr-1
- Named:IL2–CD25 complexes_Tr-11
- Named:IL2–CD25 complexes_Tr-6
- Named:IL2–CD25 complexes_Tr-7
- Named:IL2–CD25 complexes_Tr-8
- Type:Cells
- Year:2019
type: Cells
---
<html>



<div class="side-nav">
<ul>
    <div class="side-nav-item"><li><a href="#timeline" style="color: #000000;">Timeline</a></li></div>
    <div class="side-nav-item"><li><a href="#description" style="color: #000000;">Description</a></li></div>
    <div class="side-nav-item"><li><a href="#SELEX" style="color: #000000;">SELEX</a></li></div>
    <div class="side-nav-item"><li><a href="#Structure" style="color: #000000;">Structure</a></li></div>
    <div class="side-nav-item"><li><a href="#ligand-recognition" style="color: #000000;">Ligand information</a></li></div>
    <div class="side-nav-item"><li><a href="#references" style="color: #000000;">References</a></li></div>
    </ul>
</div>


<p class="header_box" id="timeline">Timeline</p>
<div class="timeline">
  <div class="entry">
  <div class="title">
    <h3><a href="https://pubmed.ncbi.nlm.nih.gov/20732639/" target="_blank" style="color:#520049">2010</a></h3>
  </div>
  <div class="body">
    <p>Review recent work concerning the structure, signaling, and function of the IL-2R, emphasizing the contribution of IL-2 for T cell-dependent activity in vivo.<sup>[<a href="#ref2" style="color:#520049">2</a>]</sup></p>
  </div>
 </div>
            
 <div class="entry">
  <div class="title">
    <h3><a href="https://pubmed.ncbi.nlm.nih.gov/23675235/" target="_blank" style="color:#520049">2011</a></h3>
  </div>
  <div class="body">
    <p>Performed gene expression and immunochemical analyses. RT-PCR revealed no IL-2 gene expression in cultured ALCL cells and ruled out the possibility of an IL-2 autocrine loop.<sup>[<a href="#ref3" style="color:#520049">3</a>]</sup></p>
  </div>
 </div>
            
 <div class="entry">
  <div class="title">
    <h3><a href="https://pubmed.ncbi.nlm.nih.gov/21719603/" target="_blank" style="color:#520049">2011</a></h3>
  </div>
  <div class="body">
    <p>Determined the effects of sIL-2Rα on IL-2 signaling and found that the sIL-2Rα-IL-2 complex promoted T-cell differentiation toward to inhibitory T(reg) cells rather than T(H)1 or T(H)17 cells. <sup>[<a href="#ref4" style="color:#520049">4</a>]</sup></p>
  </div>
 </div>
            
 <div class="entry">
  <div class="title">
    <h3><a href="https://pubmed.ncbi.nlm.nih.gov/31383650/" target="_blank" style="color:#520049">2019</a></h3>
  </div>
  <div class="body">
    <p>Determined the fraction of soluble CD25 occupied by IL2 in the serum from subjects with B-cell lymphoma. No correlation was found between the type of lymphoma and total soluble CD25 or IL2 independently.<sup>[<a href="#ref10" style="color:#520049">10</a>]</sup></p>
  </div>
 </div>
</div>



<p class="header_box" id="description">Description</p>
<p>In 2019, RNA aptamer-based assay platform designated as the "LIgand-REceptor Complex-binding APtamer," or "LIRECAP," assay that allows for quantification of the fraction of receptors occupied by a ligand was developed and used to measure the fraction of soluble CD25 occupied by IL2 in the serum of subjects with B-cell lymphoma<sup>[<a href="#ref10" style="color:#520049">10</a>]</sup>.</p>


<p class="header_box" id="SELEX">SELEX</p>
<p>In 2019, RNA aptamer-based assay platform designated as the "LIgand-REceptor Complex-binding APtamer," or "LIRECAP," assay that allows for quantification of the fraction of receptors occupied by a ligand was developed and used to measure the fraction of soluble CD25 occupied by IL2 in the serum of subjects with B-cell lymphoma<sup>[<a href="#ref10" style="color:#520049">10</a>]</sup>.<p>
<br>


<p class="header_box" id="Structure">Structure</p>
<p>The 2D structure of the figure is based on the article by ribodraw tool to draw<sup>[<a href="#ref10" style="color:#520049">10</a>]</sup>.</p>
<p>5'-GGGAGGACGAUGCGGUGAGUCGUUCCCUUCGUCCCCAGACGACUCGCCCGA-3'</p>
<img src="/images/2D/CD25_apatamer_2D.svg" alt="drawing" style="width:800px;height:400px;display:block;margin:0 auto;border-radius:0;" class="img-responsive">
<div style="display: flex; justify-content: center;"></div>



<font ><p class="header_box" id="ligand-recognition">Ligand information</p>  

<p class="blowheader_box">SELEX ligand</p>
<p>The Interleukin-2 receptor alpha chain (also called TAC antigen, P55, and mainly CD25) is a protein involved in the assembly of the high-affinity Interleukin-2 receptor, consisting of alpha (IL2RA), beta (IL2RB) and the common gamma chain (IL2RG). As the name indicates, this receptor interacts with Interleukin-2, a pleiotropic cytokine which plays an important role in immune homeostasis.-----from WiKi</p>
<table class="table table-bordered" style="table-layout:fixed;width:auto;margin-left:auto;margin-right:auto;" >
  <thead>
      <tr>
        <th onclick="sortTable(0)">Name</th>
        <th onclick="sortTable(1)">Uniprot ID</th>
        <th onclick="sortTable(2)">Pfam</th>
        <th onclick="sortTable(3)">MW</th>
        <th onclick="sortTable(4)">Amino acids sequences</th>
        <th onclick="sortTable(5)">PDB</th>
        <th onclick="sortTable(6)">Gene ID</th>
      </tr>
  </thead>
    <tbody>
      <tr>
        <td name="td0">Interleukin-2 receptor subunit alpha</td>
        <td name="td1">
        <a href="https://www.uniprot.org/uniprotkb/P01589/entry" target="_blank" style="color:#520049"><b>P01589</b></a>
        </td>
        <td name="td2"><a href="https://www.ebi.ac.uk/interpro/entry/InterPro/IPR015486/" target="_blank" style="color:#520049"><b>IPR015486</b></a></td>
        <td name="td3">30.819kDa</td>
        <td name="td4">MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQPQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI</td>
        <td name="td5">
        <a href="https://www.rcsb.org/structure/1Z92" target="_blank" style="color:#520049"><b>1Z92</b></a>
        </td>
        <td name="td6"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_001310816.1" target="_blank" style="color:#520049"><b>NM_001310816.1</b></a></td>
      </tr>
	  </tbody>
  </table>

  <p>Binding kinetics of aptamers confirm differential binding to CD25 versus IL2-CD25 complex.The binding kinetics of the aptamers toward CD25 and the IL2-CD25 complex, including association and dissociation kinetics, were determined using biolayer interferometry. The Kd, Kon, and Kdis rates for aptamer binding are summarized in Table 1 and the sensorgram in Supplementary Fig. S2. Tr-1 and Tr-7 that bound preferentially to the complex displayed a stronger affinity (lower Kd) for the IL2-CD25 complex than for the unoccupied CD25, whereas Tr-6 and Tr-8 that bound preferentially to unoccupied CD25 showed weaker affinity (higher Kd) for the IL2-CD25 complex than for unoccupied CD25. The Tr-11 aptamer that bound to the receptor and the complex equally displayed similar affinities for both (Table 1). Thus, differential affinity of aptamers for IL2-CD25 complex versus unoccupied CD25 was consistent with their differential binding preferences<sup>[<a href="#ref10" style="color:#520049">10</a>]</sup>.</p>
<table class="table table-bordered" style="table-layout:fixed;width:auto;margin-left:auto;margin-right:auto;" >
  <thead>
      <tr>
        <th onclick="sortTable(0)">Name</th>
        <th onclick="sortTable(1)">Sequence</th>
        <th onclick="sortTable(2)">Ligand</th>
        <th onclick="sortTable(3)">Affinity</th>
      </tr>
  </thead>
    <tbody>
     <tr>
      <td name="td0">Tr-1</td>
      <td name="td1">5'-GGGAGGACGAUGCGGUCCUGUCGUCUGUUCGUCCCCAGACGACUCGCCCGA-3'</td>
      <td name="td2">CD25 protein</td>
      <td name="td3">122.0 nM</td>
    </tr>
            
     <tr>
      <td name="td0">Tr-6</td>
      <td name="td1">5'-GGGAGGACGAUGCGGCGUUUCCUCUGGUUCGUCCCCAGACGACUCGCCCGA-3'</td>
      <td name="td2">CD25 protein</td>
      <td name="td3">96.9 nM</td>
    </tr>
            
     <tr>
      <td name="td0">Tr-7</td>
      <td name="td1">5'-GGGAGGACGAUGCGGUGAGUCGUUCCCUUCGUCCCCAGACGACUCGCCCGA-3'</td>
      <td name="td2">CD25 protein</td>
      <td name="td3">68.2 nM</td>
    </tr>
            
     <tr>
      <td name="td0">Tr-8</td>
      <td name="td1">5'-GGGAGGACGAUGCGGGCCGUUGUUGUGUGCCGCCCCAGACGACUCGCCCGA-3'</td>
      <td name="td2">CD25 protein</td>
      <td name="td3">35.7 nM</td>
    </tr>
            
     <tr>
      <td name="td0">Tr-11</td>
      <td name="td1">5'-GGGAGGACGAUGCGGAUUCUGGUUACUGGCCGCCCCAGACGACUCGCCCGA-3'</td>
      <td name="td2">CD25 protein</td>
      <td name="td3">46.1 nM</td>
    </tr>
	  </tbody>
  </table>
<div style="display: flex; justify-content: center;"></div>
<img src="/images/SELEX_ligand/CD25_SELEX_ligand.svg" alt="drawing" style="width:1000px;border:solid 1px #efefef;display:block;margin:0 auto;border-radius:0;" class="img-responsive">
<div style="display: flex; justify-content: center;"></div>


<p class="blowheader_box">Similar compound</p>                    
<p>We used the Dail server website to compare the structural similarities of ligand proteins, and chose the top 10 in terms of similarity for presentation. The Dali server is a network service for comparing protein structures in 3D. Dali compares them against those in the Protein Data Bank (PDB). Z-score is a standard score that is converted from an original score. The list of neighbours is sorted by Z-score. Similarities with a Z-score lower than 2 are spurious. RMSD(Root Mean Square Deviation) value is used to measure the degree to which atoms deviate from the alignment position.</p>
<table class="table table-bordered" style="table-layout:fixed;width:auto;margin-left:auto;margin-right:auto;">
      <thead>
      <tr>
        <th onclick="sortTable(1)">Named</th>
        <th onclick="sortTable(2)">CAS</th>
        <th onclick="sortTable(3)">Pubchem CID</th>
        <th onclick="sortTable(4)">Structure</th>
      </tr>
      </thead>
    <tbody>
      <tr>
      <td name="td0">1IRL-A</td>
      <td name="td1">2.5</td>
      <td name="td2">115</td>
      <td name="td3">Interleukin-2</td>
    </tr>
            
     <tr>
      <td name="td0">2Z3R-E</td>
      <td name="td1">2.7</td>
      <td name="td2">105</td>
      <td name="td3">Interleukin-15</td>
    </tr>
            
     <tr>
      <td name="td0">1BBN-A</td>
      <td name="td1">2.6</td>
      <td name="td2">108</td>
      <td name="td3">Interleukin-4</td>
    </tr>
            
     <tr>
      <td name="td0">7OX6-A</td>
      <td name="td1">3.0</td>
      <td name="td2">100</td>
      <td name="td3">Interleukin-9</td>
    </tr>
            
     <tr>
      <td name="td0">6O4O-A</td>
      <td name="td1">3.3</td>
      <td name="td2">99</td>
      <td name="td3">Interleukin-11</td>
    </tr>
            
     <tr>
      <td name="td0">8D7H-D</td>
      <td name="td1">2.8</td>
      <td name="td2">102</td>
      <td name="td3">Ciliary</td>
    </tr>
            
     <tr>
      <td name="td0">7CJN-B</td>
      <td name="td1">3.1</td>
      <td name="td2">98</td>
      <td name="td3">Interleukin</td>
    </tr>
            
     <tr>
      <td name="td0">2L3Y-A</td>
      <td name="td1">2.8</td>
      <td name="td2">96</td>
      <td name="td3">Interleukin-6</td>
    </tr>
            
     <tr>
      <td name="td0">8DH9-D</td>
      <td name="td1">3.6</td>
      <td name="td2">104</td>
      <td name="td3">Leptin</td>
    </tr>
            
     <tr>
      <td name="td0">1BUY-A</td>
      <td name="td1">3.2</td>
      <td name="td2">109</td>
      <td name="td3">Protein</td>
    </tr>
    </tbody>
  </table>
                 
<p class="header_box" id="references">References</p>
                
<a id="ref1"></a><font><strong>[1] The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.</strong></font><br />
Waldmann T. A.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/16868550/" target="_blank" style="color:#520049">Nature reviews. Immunology, 6(8), 595–601. (2006)</a>
<br/>
            
<a id="ref2"></a><font><strong>[2] Interleukin-2 receptor signaling: at the interface between tolerance and immunity. </strong></font><br />
Malek, T. R., & Castro, I. <br />
<a href="https://pubmed.ncbi.nlm.nih.gov/20732639/" target="_blank" style="color:#520049">Immunity, 33(2), 153–165. (2010)</a>
<br/>
            
<a id="ref3"></a><font><strong>[3]  Interleukin-2 functions in anaplastic large cell lymphoma cells through augmentation of extracellular signal-regulated kinases 1/2 activation.</strong></font><br />
Ito, M., Zhao, N., Zeng, Z., Zhou, X., Chang, C. C., & Zu, Y.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/23675235/" target="_blank" style="color:#520049">International journal of biomedical science : IJBS, 7(3), 181–190. (2011)</a>
<br/>
            
<a id="ref4"></a><font><strong>[4] Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.</strong></font><br />
Yang, Z. Z., Grote, D. M., Ziesmer, S. C., Manske, M. K., Witzig, T. E., Novak, A. J., & Ansell, S. M.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/21719603/" target="_blank" style="color:#520049">Blood, 118(10), 2809–2820. (2011)</a>
<br/>
            
<a id="ref5"></a><font><strong>[5] Induced and natural regulatory T cells in human cancer.</strong></font><br />
Whiteside TL, Schuler P, Schilling B.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/22849383/" target="_blank" style="color:#520049">Expert opinion on biological therapy, 12(10), 1383–1397. (2012)</a>
<br/>
            
<a id="ref6"></a><font><strong>[6]  Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.</strong></font><br />
Mir, M. A., Maurer, M. J., Ziesmer, S. C., Slager, S. L., Habermann, T., Macon, W. R., Link, B. K., Syrbu, S., Witzig, T., Friedberg, J. W., Press, O., LeBlanc, M., Cerhan, J. R., Novak, A., & Ansell, S. M. <br />
<a href="https://pubmed.ncbi.nlm.nih.gov/25422100/" target="_blank" style="color:#520049">Blood, 125(6), 992–998. (2015)</a>
<br/>
            
<a id="ref7"></a><font><strong>[7] Evolving synergistic combinations of targeted immunotherapies to combat cancer.</strong></font><br />
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Pérez Gracia, J. L., & Haanen, J. <br />
<a href="https://pubmed.ncbi.nlm.nih.gov/26205340/" target="_blank" style="color:#520049">Nature reviews. Cancer, 15(8), 457–472. (2015)</a>
<br/>
            
<a id="ref8"></a><font><strong>[8] Nucleic acid aptamers in cancer research, diagnosis and therapy.</strong></font><br />
Ma, H., Liu, J., Ali, M. M., Mahmood, M. A., Labanieh, L., Lu, M., Iqbal, S. M., Zhang, Q., Zhao, W., & Wan, Y.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/25561050/" target="_blank" style="color:#520049">Nucleic acid aptamers in cancer research, diagnosis and therapy. Chemical Society reviews, 44(5), 1240–1256. (2015)</a>
<br/>
            
<a id="ref9"></a><font><strong>[9] Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. </strong></font><br />
Binder, M., O'Byrne, M. M., Maurer, M. J., Ansell, S., Feldman, A. L., Cerhan, J., Novak, A., Porrata, L. F., Markovic, S., Link, B. K., & Witzig, T. E. <br />
<a href="https://pubmed.ncbi.nlm.nih.gov/28383112/" target="_blank" style="color:#520049">American journal of hematology, 92(8), 752–758. (2017)</a>
<br/>
            
<a id="ref10"></a><font><strong>[10] An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.</strong></font><br />
Veeramani, S., Blackwell, S. E., Thiel, W. H., Yang, Z. Z., Ansell, S. M., Giangrande, P. H., & Weiner, G. J.<br />
<a href="https://pubmed.ncbi.nlm.nih.gov/31383650/" target="_blank" style="color:#520049">Cancer immunology research, 7(9), 1511–1522. (2019)</a>
<br/>




<html lang="en">
    <head>
      <meta charset="utf-8" />
      <meta name="viewport" content="width=device-width, user-scalable=no, minimum-scale=1.0, maximum-scale=1.0">
      <meta http-equiv="X-UA-Compatible" content="IE=edge">
      <!-- Molstar CSS & JS -->
      <link rel="stylesheet" type="text/css" href="https://cdn.jsdelivr.net/npm/pdbe-molstar@3.3.0/build/pdbe-molstar.css">
      <script src="https://cdn.jsdelivr.net/npm/pdbe-molstar@3.3.0/build/pdbe-molstar-plugin.js"></script>
        <style>
          * {
              margin: 0;
              padding: 0;
              box-sizing: border-box;
          }
          .msp-plugin ::-webkit-scrollbar-thumb {
              background-color: #474748  !important;
          }
          .msp-plugin .msp-layout-standard {
              border: 1px solid #efefef;
          }
          .viewerSection1 {
            padding-top: 0px;
          }
          .controlsSection1 {
            width: 300px;
              display: flex;
              float:left;
              padding: 0px 0 0 0;
              height:25px;
            }
            .controlBox1 {
              border: 0px solid lightgray;
              padding: 0px;
              margin-bottom: 0px;
            }
          #myViewer1{
            float:left;
            width:500px;
            height: 500px;
            position:relative;
          }
        </style>
    </head>
    <script>
      var viewerInstance1 = new PDBeMolstarPlugin();
      var options1 = {
        customData:{
        url:'/pdbfiles/1RAW-3D.pdb',
        format: 'pdb'},
        hideCanvasControls: ['expand', 'selection', 'animation', 'controlToggle'],
        bgColor: {r:255, g:255, b:255},
        }
      var viewerContainer1 = document.getElementById('myViewer1');
      viewerInstance1.render(viewerContainer1, options1);
  window.addEventListener('load', function() {
    var colorSelectionButton1 = document.querySelector('.controlsSection1 button');
    colorSelectionButton1.click();
  });
    </script>

    </html>